Seek Returns

ABBV vs. EXEL: AbbVie vs. Exelixis Stock Comparison

How do AbbVie (ABBV) and Exelixis (EXEL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Exelixis (EXEL) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for AbbVie (ABBV) and Exelixis (EXEL)
Profile ItemABBVEXEL
NameAbbVie Inc.Exelixis Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization514.92 billion USD16.98 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJanuary 2, 2013April 17, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ABBV
EXEL
GSPC
Loading price history…
AbbVie (ABBV) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AbbVie (ABBV) and Exelixis (EXEL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AbbVie (ABBV) and Exelixis (EXEL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Total Return (1Y)37.33%74.98%
Total Return (3Y, Annualized)32.74%50.33%
Total Return (5Y, Annualized)24.73%31.10%

Risk Profile

Drawdown History

ABBV
EXEL
GSPC
Loading price history…
AbbVie (ABBV) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AbbVie (ABBV) and Exelixis (EXEL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Volatility (1Y, Annualized)25.65%34.17%
Beta (5Y)0.210.41
Max Drawdown (5Y)-21.92%-35.41%
Avg. Volume (3M)4.76M2.33M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ABBV and EXEL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Sharpe Ratio (1Y)1.292.07
Sortino Ratio (1Y)2.023.23

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Exelixis (EXEL) earns 44.32% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ABBV
--

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): ABBV does not report ROE, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max
18.05%
ABBV
15.67%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both AbbVie (ABBV) at 39.59% and Exelixis (EXEL) at 40.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max
83.12%
ABBV
39.59%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
ROE (TTM)--44.32%
ROA (TTM)10.74%23.52%
Net Margin (TTM)15.67%35.45%
Operating Margin (TTM)39.59%40.75%
Gross Margin (TTM)73.72%96.26%

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Exelixis (EXEL) at 6.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AbbVie (ABBV) at -0.84% and Exelixis (EXEL) at 57.95% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Revenue Growth (YoY)8.57%6.98%
Revenue Growth (3Y CAGR)1.75%12.93%
EPS Growth (YoY)-0.84%57.95%
EPS Growth (3Y CAGR)-29.03%70.59%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ABBV
0.87
Min
0.10

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Exelixis (EXEL) carries debt-to-equity ratio of 0.09 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
ABBV
--

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): ABBV does not report debt-to-equity ratio, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Current Ratio (MRQ)0.873.21
Debt / Equity (MRQ)--0.09
Net Debt / EBITDA2.21-0.71

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV
2.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Exelixis (EXEL) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV
117.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
Dividend Yield (TTM)2.40%0.00%
Dividend Payout Ratio (TTM)117.35%0.00%

Valuation

P/E Ratio (TTM)

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max
85.34
ABBV
50.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and Exelixis (EXEL) at 6.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max
58.18
Q3
25.77
ABBV
7.80
Median
7.30
Q1
3.01
Min
0.01

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Exelixis (EXEL) reports 9.28, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
ABBV
-112.34

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
AbbVie (ABBV) vs. Exelixis (EXEL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Exelixis (EXEL)
MetricABBVEXEL
P/E Ratio (TTM)50.0520.83
P/S Ratio (TTM)7.806.80
P/B Ratio (MRQ)-112.349.28
Free Cash Flow Yield (TTM)3.44%4.47%